recognized for our innovation, quality, and customer convenience, labcorp delivers timely, accurate results for improved patient care. with scientific expertise in esoteric testing, genomics, and clinical and anatomic pathology, labcorp performs more than one million tests on approximately 400,000 samples each day. labcorp is a pioneer in applying advances in medicine and science to laboratory testing, with more than 35 years of experience in serving physicians and their patients. labcorp operates a sophisticated laboratory network, with corporate headquarters in burlington, nc, and more than 34,000 employees worldwide. our more than 220,000 clients include physician offices, hospitals, managed care organizations, and biotechnology and pharmaceutical companies. laboratory corporation of america holdings is listed on the new york stock exchange (nyse) under ticker symbol lh.
Company profile
Ticker
LH, LH
Exchange
Website
CEO
Adam Schechter
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Quest Diagnostics • Fortrea • Radnet • Akumin • Burning Rock Biotech • Guardant Health • Genomic Health • Exact Sciences • Invitae • Natera ...
Former names
NATIONAL HEALTH LABORATORIES HOLDINGS INC
SEC CIK
Corporate docs
Subsidiaries
1957285 Ontario Inc. • 2089729 Ontario, Inc. • 2248848 Ontario Inc. • 3065619 Nova Scotia Company • 3257959 Nova Scotia Company • 896988 Ontario Limited • 9279-3280 Quebec Inc. • Accupath Diagnostic Laboratories, Inc. • Beacon Laboratory Benefit Solutions, Inc. • BeaconLBS IPA, Inc. ...
IRS number
133757370
LH stock data
Latest filings (excl ownership)
8-K
Labcorp Announces 2024 First Quarter Results
25 Apr 24
8-K
Labcorp Declares Quarterly Dividend
11 Apr 24
ARS
2023 FY
Annual report to shareholders
4 Apr 24
DEFA14A
Additional proxy soliciting materials
4 Apr 24
DEF 14A
Definitive proxy
4 Apr 24
8-K
Regulation FD Disclosure
27 Mar 24
10-K
2023 FY
Annual report
26 Feb 24
8-K
Labcorp Announces 2023 Fourth Quarter and Full Year Results
15 Feb 24
8-K
Regulation FD Disclosure
16 Jan 24
8-K
Labcorp Declares Quarterly Dividend
12 Jan 24
Transcripts
LH
Earnings call transcript
2024 Q1
25 Apr 24
LH
Earnings call transcript
2023 Q4
15 Feb 24
LH
Earnings call transcript
2023 Q3
26 Oct 23
LH
Earnings call transcript
2023 Q2
27 Jul 23
LH
Earnings call transcript
2023 Q1
25 Apr 23
LH
Earnings call transcript
2022 Q4
16 Feb 23
LH
Earnings call transcript
2022 Q3
27 Oct 22
LH
Earnings call transcript
2022 Q2
28 Jul 22
LH
Earnings call transcript
2022 Q1
28 Apr 22
LH
Earnings call transcript
2021 Q4
10 Feb 22
Latest ownership filings
4
GLENN A EISENBERG
17 Apr 24
4
Mark S Schroeder
3 Apr 24
4
Amy B. Summy
3 Apr 24
4
Megan D. Bailey
3 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
4
der Vaart Sandra D van
29 Mar 24
4
Brian J Caveney
29 Mar 24
4
Mark S Schroeder
29 Mar 24
4
Adam H Schechter
29 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 727.90 mm | 727.90 mm | 727.90 mm | 727.90 mm | 727.90 mm | 727.90 mm |
Cash burn (monthly) | 400.90 mm | (no burn) | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 2.76 bn | n/a | n/a | n/a | n/a | n/a |
Cash remaining | -2.03 bn | n/a | n/a | n/a | n/a | n/a |
Runway (months of cash) | -5.1 | n/a | n/a | n/a | n/a | n/a |
Institutional ownership, Q4 2023
64.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 754 |
Opened positions | 98 |
Closed positions | 200 |
Increased positions | 236 |
Reduced positions | 280 |
13F shares | Current |
---|---|
Total value | 11.47 tn |
Total shares | 53.99 mm |
Total puts | 17.30 k |
Total calls | 63.20 k |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 9.75 mm | $2.22 tn |
STT State Street | 3.77 mm | $856.95 bn |
Wellington Management | 2.25 mm | $510.97 bn |
MS Morgan Stanley | 1.93 mm | $439.62 bn |
JPM JPMorgan Chase & Co. | 1.51 mm | $343.50 bn |
Dimensional Fund Advisors | 1.45 mm | $328.76 bn |
Diamond Hill Capital Management | 1.42 mm | $323.63 bn |
Ubs Global Asset Management Americas | 1.19 mm | $271.26 bn |
NTRS Northern Trust | 1.16 mm | $264.40 bn |
Veritas Investment Partners | 1.14 mm | $259.13 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Apr 24 | Eisenberg Glenn A | Common Stock | Payment of exercise | Dispose F | No | No | 203.32 | 4,496 | 914.13 k | 40,556 |
15 Apr 24 | Eisenberg Glenn A | Common Stock | Option exercise | Acquire M | No | No | 0 | 10,229 | 0.00 | 45,052 |
15 Apr 24 | Eisenberg Glenn A | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 10,229 | 0.00 | 5,477 |
1 Apr 24 | Megan D. Bailey | Common Stock | Payment of exercise | Dispose F | No | No | 216.35 | 69 | 14.93 k | 436 |
1 Apr 24 | Megan D. Bailey | Common Stock | Option exercise | Acquire M | No | No | 0 | 205 | 0.00 | 505 |
1 Apr 24 | Megan D. Bailey | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 205 | 0.00 | 5,407 |
1 Apr 24 | Amy B. Summy | Common Stock | Sell | Dispose S | No | Yes | 217.29 | 3,500 | 760.52 k | 3,975 |
1 Apr 24 | Schroeder Mark S | Common Stock | Sell | Dispose S | No | Yes | 217.29 | 6,477 | 1.41 mm | 5,036.143 |
28 Mar 24 | van der Vaart Sandra D | Common Stock | Sell | Dispose S | No | Yes | 216.74 | 3,553 | 770.08 k | 7,636.979 |
27 Mar 24 | van der Vaart Sandra D | Common Stock | Payment of exercise | Dispose F | No | No | 216.57 | 2,605 | 564.16 k | 11,189.979 |
News
Labcorp's Q1 Revenue Surpasses Forecasts; Analysts Scrutinize Invitae Deal
25 Apr 24
Laboratory Corp Q1 2024 Adj EPS $3.68 Beats $3.48 Estimate, Sales $3.177B Beat $3.117B Estimate
25 Apr 24
Reported Earlier, Labcorp Wins Bid For Invitae Assets To Boost Specialty Testing In Oncology And Rare Diseases
25 Apr 24
Labcorp Reports Strategic Expansion Of Its Precision Oncology Portfolio
8 Apr 24
Labcorp Launches Labcorp Plasma Detect Extending Leadership Into Molecular Residual Disease (MRD) Clinical Research
5 Apr 24
Press releases
Labcorp Announces 2024 First Quarter Results
25 Apr 24
Labcorp Announces Winning Bid for Select Assets of Invitae
24 Apr 24
Invitae Enters into Agreement with Labcorp for Sale of Business
24 Apr 24
Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and Brain Injuries Using a Blood Draw
15 Apr 24
Labcorp Declares Quarterly Dividend
11 Apr 24